GENET-news
To stay informed you can subscribe to the GENET-news list.
2007-01-11 | permalink
SemBioSys' plant-produced insulin chemically and physiologically equivalent to commercial insulin in animal studies
SemBioSys Genetics Inc., a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, today announced that its proprietary plant-produced insulin has been demonstrated in animal models to be chemically, structurally and functionally equivalent to U.S. pharma grade human insulin. The results of analytical, in vitro and in vivo assays confirm that insulin produced in safflower, SemBioSys’ commercial crop, is indistinguishable from human insulin analytically and physiologically.
Overview
News
2007-01-11 | permalink
SemBioSys' plant-produced insulin chemically and physiologically equivalent to commercial insulin in animal studies
SemBioSys Genetics Inc., a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, today announced that its proprietary plant-produced insulin has been demonstrated in animal models to be chemically, structurally and functionally equivalent to U.S. pharma grade human insulin. The results of analytical, in vitro and in vivo assays confirm that insulin produced in safflower, SemBioSys’ commercial crop, is indistinguishable from human insulin analytically and physiologically.
GENET-news & GENET-forum
GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by 
email.
The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the coordinator for membership and subscription.